LeafRider wrote: Fog brings forward a solid number of patients that are affected with terminal cancer in Canada alone so why not take a look at what we're working with in detail. Let's make some modest assumptions to try and assess how much revenue Tetra could create if only 50% of the of the terminal cancer patients who suffer with pain who would actually seek out support from the 1st smokable cannabis product with a DIN# (insurance coverage). Believe me if you can get your taxed medication paid for you will. Smoking Cannabis is safe, there are countless studies that point to it's safety. So Gkmack, shut your mouth already spreading fake news!
The World Health Organization (WHO) is no small potato!! Link: https://www.livescience.com/61213-marijuana-cannabidiol-world-health-organization.html
We won't factor in "growth" at the moment because it's somethign that one can do at the end of the process to help understand our projected revenues in years to come. In general I see these numbers will grow substantially with the next 5 years with the aging population. So for sake of ease of calculations lets assume 50,000 patients in Canada will have PPP001 available to them, in addition to RxPrinceps and PPP005 (cannabis oil) at some point, but we'll keep this simple and look just at PPP001.
Personally I don't think we're being overzealous at all, in fact one could easily say lets tack on total market in Israel, Portugal, etc, etc... There will be other international patient exposure from large pharma that have the cash to promote, market and distribute PPP001 and Tetra will collect revenue from these agreements.
Canadian Calculations:
- Assume $500 startup package includes medical device and 1 month supply of the blister packed cannabis pellets. There after we're going to assume at least $200 a month for the cannabis pellets since 1 ounce of cannabis is roughly $200 a month, and it's simple enough that no one should have an issue with this assumption. Except for the rat bashers of course, but they are set to ignore anyway (or at least should be).
- Since we're looking at annual revenues, we'll go (11x$200)+$500= $2700 annual revenue per patient. x 50,000 patients (Canada alone).
= $135 million (in just Canada)
If you want to appease those who pefer low end estimates go with how many patients need to be taking PPP001 annually to create $100,000,000 in revenue for Tetra? That's about 37,000 patients. So on a smaller scale you could say 3700 patients represents $10 million in annual revenues. I don't know about the rest of you but 3700 patients is going to be highly obtainable prior to 2020. Sure the drug product may not have an official DIN#, but the drug itself will be in the hands of patients that can benefit from the drug and we'll be seeing these types of revenues at some point.
Plus if you would like to factor in the fact this an international drug product that will be in the US, Germany, Brazil, etc. etc. at some point... You can see that Tetra will become a GW Pharma type company at some point. Even if you factor in the fact that
Azevedos Industria Farmaceutica, S.A. (Portugal) and Kamada (Israel) will be making significant revenues off of this drug product, Tetra's lump sum payments and continued royalties will help pay the bills down the line. This is real folks, this isn't a pipe dream. You're investing in the whole package / plan! Fogcity87 wrote: In 2018 it is estimated 80800 patients will be terminally ill from cancer in Canada (as per statitics canada). Studies have shown that over 50 percent of cancer patients suffer from pain.
PS - Gkmack, shut your yap already, you're clueless and people are well aware that you're shorting the stock and bashing it at will. Not a single real life person CARES WHAT YOU SAY OR DO HERE!!